期刊文献+

HLA-A*02-B*46 Haplotype: an Adverse Prognostic Factor in Han Patients with Nasopharyngeal Carcinoma

HLA-A*02-B*46 Haplotype: an Adverse Prognostic Factor in Han Patients with Nasopharyngeal Carcinoma
下载PDF
导出
摘要 Epidemiological studies have shown that human leukocyte antigen(HLA) allelic polymorphisms are closely correlated to susceptibility to nasopharyngeal carcinoma(NPC), and in a previous study, we showed that HLA-B*46 and HLA-A*02-B*46 haplotypes were strongly associated with NPC susceptibility. In this retrospective study, we investigated the phenotype of the HLA-A and HLA-B alleles and haplotypes and correlated these data to the clinical and pathological parameters of NPC to understand the role of HLA alleles and haplotypes in NPC prognosis. The cohort comprised 117 NPC patients from a Han population in Xinjiang. The local recurrence-free survival(LRFS), distant metastasis-free survival(DMFS), disease-free survival(DFS), and overall survival(OS) were analyzed. The 5-year DMFS of the HLA-A*02-B*46 haplotype carriers and non-carriers was 66.4% and 90.3%, respectively. In addition, age was found to be a prognostic factor for LRFS, DFS, and OS(P=0.032, 0.040, and 0.013, respectively). We found that the HLA-A*02-B*46 haplotype might be a prognostic marker in addition to the traditional TNM staging in patients with NPC. Epidemiological studies have shown that human leukocyte antigen(HLA) allelic polymorphisms are closely correlated to susceptibility to nasopharyngeal carcinoma(NPC), and in a previous study, we showed that HLA-B*46 and HLA-A*02-B*46 haplotypes were strongly associated with NPC susceptibility. In this retrospective study, we investigated the phenotype of the HLA-A and HLA-B alleles and haplotypes and correlated these data to the clinical and pathological parameters of NPC to understand the role of HLA alleles and haplotypes in NPC prognosis. The cohort comprised 117 NPC patients from a Han population in Xinjiang. The local recurrence-free survival(LRFS), distant metastasis-free survival(DMFS), disease-free survival(DFS), and overall survival(OS) were analyzed. The 5-year DMFS of the HLA-A*02-B*46 haplotype carriers and non-carriers was 66.4% and 90.3%, respectively. In addition, age was found to be a prognostic factor for LRFS, DFS, and OS(P=0.032, 0.040, and 0.013, respectively). We found that the HLA-A*02-B*46 haplotype might be a prognostic marker in addition to the traditional TNM staging in patients with NPC.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2016年第5期700-704,共5页 华中科技大学学报(医学英德文版)
基金 supported by grants from the Chinese International Cooperation Project(No.2012DFA31560) Key Laboratory Projects of Xinjiang Uygur Autonomous Region(No.2015KL021) the Achievement Promotion Projects of the Autonomous Region(No.201554142)
关键词 Carcinoma recurrence prognostic staging metastasis prognosis retrospective distant alleles haplotype Carcinoma recurrence prognostic staging metastasis prognosis retrospective distant alleles haplotype
  • 相关文献

参考文献2

二级参考文献83

  • 1吴国光,邓志辉,高素青,程良红,金士正,周丹,李桢,邹红岩,张旋,魏天莉,程曦,王大明.6965名汉族骨髓供者HLA多态性分析[J].中华血液学杂志,2004,25(8):473-477. 被引量:96
  • 2王志鹏,郭实士,余平.湖南汉族人群HLA-DR位点等位基因多态性与鼻咽癌的相关性研究[J].中国病理生理杂志,2005,21(5):1014-1015. 被引量:6
  • 3遗传因素、环境因素及EB病毒在鼻咽癌发生中作用的研究[J].中国肿瘤,1995,4(3):24-25. 被引量:5
  • 4Kwong DL, Pow EH, Sham JS, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function [J]. Cancer, 2004, 101 (7) : 1584-1593.
  • 5Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience [J]. Int J Radiat Oncol Biol Phys, 2002,53( 1 ) : 12-22.
  • 6Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience [J]. Int J Radiat Oncol Biol Phys, 2004,60(5) : 1440-1450.
  • 7Lin SJ, Pan JJ, Han L, et al. Nsopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: rdport on the 3-year outcome of a prospective series [J]. Int J Radiat Oncol Biol Phys, 2009,76( 1 ) : 1-8.
  • 8Radiation Theapy Oncology Group Protocol 02-25. Available at: http ://www.rtog.org/memebers/protocols/0225/0225.pdf. Accessed August 26, 2008.
  • 9Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) [ J ]. Int J Radiat Oncol Biol Phys, 1995,31 (5) : 1341-1346.
  • 10Hunt MA, Zelefsky MJ, Wolden S, et al. Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer [J]. Int J Radar Oncol Biol Phys, 2001, 49 : 623-632.

共引文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部